Retreatment with brentuximab vedotin in CD30-positive hematologic malignancies: A phase II study.

被引：0

作者：

Bartlett, Nancy

Brice, Pauline

Chen, Robert W.

Fanale, Michelle A.

Gopal, Ajay K.

Matous, Jeffrey

Rosenblatt, Joseph David

Grove, Laurie E.

Forero-Torres, Andres

机构：

[1] Washington Univ, Siteman Canc Ctr, St Louis, MO USA

[2] Hosp Saint Louis, Paris, France

[3] City Hope Natl Med Ctr, Duarte, CA USA

[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[5] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[6] Colorado Blood Canc Inst, Denver, CO USA

[7] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

[8] Seattle Genet Inc, Bothell, WA USA

[9] Univ Alabama Birmingham, Birmingham, AL USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

8027

引用

页数：1

共 50 条

[21] Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies
Gualberto, Antonio
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (02) : 205 - 216
[22] OBJECTIVE RESPONSES WITH SGN-35 RETREATMENT IN CD30-POSITIVE HEMATOLOGIC MALIGNANCIES: A CASE SERIES
Bartlett, N.
Grove, L. E.
Kennedy, D.
Sievers, E. L.
Forero-Torres, A.
HAEMATOLOGICA, 2010, 95 : S30 - S30
[23] Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies
Li, Hong
Han, Tae H.
Hunder, Naomi N.
Jang, Graham
Zhao, Baiteng
JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (09): : 1148 - 1158
[24] Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
Zhao, Baiteng
Chen, Robert
O'Connor, Owen A.
Gopal, Ajay K.
Ramchandren, Radhakrishnan
Goy, Andre
Matous, Jeffrey V.
Fasanmade, Adedigbo A.
Manley, Thomas J.
Han, Tae H.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (03) : 696 - 705
[25] Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Younes, Anas
Bartlett, Nancy L.
Leonard, John P.
Kennedy, Dana A.
Lynch, Carmel M.
Sievers, Eric L.
Forero-Torres, Andres
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (19): : 1812 - 1821
[26] Brentuximab Vedotin in CD30-Positive Lymphomas: A SIE, SIES, and GITMO Position Paper
Zinzani, Pier Luigi
Corradini, Paolo
Gianni, Alessandro M.
Federico, Massimo
Santoro, Armando
Vitolo, Umberto
Barosi, Giovanni
Tura, Sante
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2015, 15 (09): : 507 - 513
[27] Brentuximab Vedotin in Combination with Nivolumab in CD30+Malignancies Refractory to Brentuximab Vedotin
Poh, Christina
Lynch, Ryan C.
Warren, Edus H.
Ujjani, Chaitra S.
Smith, Stephen D.
Shinohara, Michi M.
Fromm, Jonathan R.
Fan, Xinyi
Voutsinas, Jenna M.
Wu, Qian
Naylor, Laura
Rasmussen, Heather
Gopal, Ajay K.
BLOOD, 2023, 142
[28] Advanced-stage CD30-positive mycosis fungoides: Clinical experience with brentuximab vedotin
Vico-Alonso, Cristina
Jose Andres-Lencina, Juan
Aragon-Miguel, Raquel
Calleja-Algarra, Alba
Pinilla-Martin, Belen
Sanchez-Velazquez, Alba
Munoz-Gonzalez, Hector
Penalba, Maria
Velasco Tamariz, Virginia
Postigo LLorente, Concepcion
Ortiz-Romero, Pablo L.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB173 - AB173
[29] Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas
Wagner, Sandro M.
Melchardt, Thomas
Egle, Alexander
Magnes, Teresa
Skrabs, Cathrin
Staber, Philipp
Simonitsch-Klupp, Ingrid
Panny, Michael
Lehner, Barbara
Greil, Richard
Keil, Felix
Jager, Ulrich
Sillaber, Christian
EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 104 (03) : 251 - 258
[30] Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience
Rothe, Achim
Sasse, Stephanie
Goergen, Helen
Eichenauer, Dennis A.
Lohri, Andreas
Jaeger, Ulrich
Bangard, Christopher
Boell, Boris
Baildon, Michael von Bergwelt
Theurich, Sebastian
Borchmann, Peter
Engert, Andreas
BLOOD, 2012, 120 (07) : 1470 - 1472

← 1 2 3 4 5 →